» Download Public Reports
46 reports
- Company report
- November 2012
- 8 pages
- by Corporation
... Potential generic equivalents), potential liability for sales of generic medicines prior to a final resolution of outstanding patent litigation, including that relating to our generic version of protonix ...
July 2012
... Of our main corporate products. First of all, the reduction of lercanidipine sales is due mainly to lower volumes sold as a result of generic competition. Direct sales in italy are down by 11 ...
November 2012
... European generic medicines association 1/11 position paper ega contribution to ec public consultation on General report on experience acquired as a result ...
July 2012
... In-pharmatechnologist.Com/ingredients/sandoz-opens-slovenian-biosimilars-production- plant. [Accessed february 17, 2012] The european generic medicines association (2010). Faq on biosimilar medicines. Available from - [accessed march 12 ...
September 2012
... Costs ega improving competitiveness increasing market share promoting sustainable pricing quicker access to the market (stm) challenges for the european generic medicines market inquiry identifies ...
December 2012
... generic medicines company source: ega and ec - sector inquiry unsustainable challenge more regulation/ increased costs price decrease national level national + eu level 26 positive trends ...
January 2013
... generic medicines industry faces strong competition from trional producers such as the us and japan, along with growing competition from fast developing emerging market economies from the brick7 ...
December 2012
... Of international competition 20 year patent + up to 5 year spc leading countries in number of cans for biosimilars european generic medicines industry: major contributor to employment ...